Last updated: 2026-09-16 09:45:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Oculis Holding AG (OCS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $10,22, with a market capitalisation of $588,60M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10,00 to $34,48. This page covers its latest market performance, valuation, price trends and company information.
$588,60M | |
$10,10 | |
$34,48 | |
$6,26 | |
$10,07 | |
10,00 | |
313,36K | |
-- | |
$34,48 | |
$10,00 | |
-- | |
-- |
Oculis Holding AG (OCS) is trading at $10,22 in pre-market trading as of 2026-09-16 09:06:00, up 1,52% ($0,15) from the previous close of $10,07
Pre-market trading shows how investors are pricing OCS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Oculis Holding AG (OCS) moved from $12,17 to $10,22, representing a decline of 16,00% ($1,95).
The stock traded between $10,00 and $12,66 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 162,27 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0,9%
OCS is currently trading at $10,22, placing it 0,9% of the way from its 52-week low of $10,00 to its 52-week high of $34,48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
| Employees | 60 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Oculis Holding AG (OCS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.